Life Science Intelligence

The  global cardiac ablation devices market  is witnessing a significant transformation thanks to the emergence of pulsed field ablation (PFA) technology. Since its introduction in 2021, PFA has been rapidly changing the way atrial fibrillation (AFib) is treated, providing an alternative to traditional methods like radiofrequency (RF) and cryoablation. This innovative technology is now driving growth in the pulsed field ablation market, which is expected to see rapid expansion over the next few years. A New Era for Cardiac Ablation with Pulsed Field Ablation PFA uses non-thermal electroporation to selectively target myocardial cells while sparing non-cardiac tissue, offering several advantages over traditional ablation techniques. This technology significantly reduces procedure times — by 30% to 50% — resulting in better cost-efficiency and improved patient outcomes. Clinical data supports the notion that PFA may eventually match or even exceed the effectiveness of RF and cryo...

Under the direction of Founder and CEO Yosef Safi Harb, Happitech is rethinking cardiac monitoring with a next-generation smartphone-based platform, a CE-certified solution that enables long-term heart rate and rhythm tracking using only a smartphone, while also integrating with wearables and medical devices equipped with PPG sensors. By leveraging photoplethysmography (PPG) through a smartphone’s camera and flash, or any compatible sensor or wearable, Happitech delivers medical-grade insights anytime, anywhere. The platform is intended to support clinical decision-making, expand access, and reshape how atrial fibrillation (AFib) is detected and monitored today, and how other heart conditions are detected and monitored tomorrow. The Current Landscape Happitech’s foundational belief is that heart monitoring should be accessible, scalable, and effortless. Today, their CE-certified platform is already integrated into more than 50% of Dutch cardiology hospitals and supports long-term cardi...

The  global electrosurgical devices market  is undergoing a profound transformation, driven by innovation in surgical techniques and the growing adoption of robotic surgery. The increasing integration of electrosurgical tools into robotic platforms is reshaping the competitive landscape and enhancing the precision of soft tissue surgeries. As the demand for less invasive surgeries rises, electrosurgical devices play a crucial role in this shift, providing surgeons with advanced tools for tissue cutting, coagulation, and ablation. This article delves into the current state of the electrosurgical devices market, focusing on key industry trends, major players, and emerging technologies that are driving growth in 2025. It also explores how the landscape is shifting, with companies like Medtronic, Johnson & Johnson MedTech, and Intuitive Surgical leading the charge in robotic-assisted surgeries. Overview of the Electrosurgical Devices Market in 2025 Electrosurgical devices, whi...

  The   transcatheter aortic valve replacement (TAVR) market   is undergoing significant evolution. As the demand for less invasive heart valve procedures continues to rise, the competitive landscape is rapidly shifting. Medtech giants like Medtronic and Edwards Lifesciences remain dominant, but innovation continues to play a crucial role in reshaping the future of the TAVR market. This article dives into the current state of the TAVR market, key industry players, and the forces driving growth, as well as recent industry moves such as Boston Scientific’s decision to exit the TAVR space. The TAVR Landscape in 2025 Since its U.S. approval in 2011, TAVR has transformed the treatment of severe aortic stenosis. Particularly beneficial for high-risk patients who are not candidates for open-heart surgery, TAVR has quickly become the standard procedure for aortic valve replacement in many countries. The procedure’s appeal lies in its less invasive nature, shorter recovery time, a...

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $17M in new funds, achieve regulatory clearances, appoint new executives, and much more on the road to  LSI Europe  ’25 in London (September 7–11). Adialante Received a $1.18M National Science Foundation SBIR Phase II award to advance the development of its compact, silent, and low-cost MRI technology. The funding brings Adialante’s total raised to nearly $3M as the team works to expand access to high-quality medical imaging worldwide. Asabys Partners Promoted Maite Malet and Isabel Jiménez Bernal to Principal in recognition of their leadership and impact across the firm’s healthcare investment strategy. Asabys continues to strengthen its position in health-tech and biopharma by advancing transformative technologies alongside top industry talent. Berkshire Biomedical Was awarded Phase I of a two-phase Fast-Track SBIR grant from the National Institutes of ...

Join moderator Amir Soltanianzadeh and Dr. Asif Ali from the American Heart Association as they explore how wearable technology is revolutionizing cardiac care and shaping its future. For more information watch this video:  https://www.lifesciencemarketresearch.com/videos/signature-series-the-future-of-wearables-in-cardiac-care-lsi-usa-25